|Day Low/High||4.54 / 4.67|
|52 Wk Low/High||3.36 / 26.12|
I've stayed primarily to those names that have plenty of cash on the balance sheet and should be just fine once saner heads prevail.
Let's check the charts of this bio pharmaceutical company that develops drugs for cardiovascular disease.
Buyers will need patience and tolerance for risk as AMRN is likely to continue to trade sideways and could decline, according to the charts and indicators.
Pharmaceutical firm AMRN developments therapeutics for the treatment of cardiovascular diseases.
The planned acquisition of The Medicines Company by Novartis spurs prospects of other deals in the drug business.
For many market players, corrective action at this point is a positive rather than a negative.
What I have found is that the real value of charts is as a trade management tool.
I added shares this morning and will be looking for more entry points as it develops.
Market players are trying to decipher Fed Chair Powell's latest words.
Market players are more skeptical of the quick moves on U.S.-China trade news.
Poor trading action in Lyft will likely create some distrust of upcoming IPOs, and Uber in particular.
Valuation and all the other issues that are being discussed are secondary to the price action.
While there is some positive movement, it has not been sustained which makes trading quite tricky.
China negotiations resume today and the potential for weekend news is high.
So far there is no bounce in Kraft Heinz which is not a good sign.
It is the action in secondary stocks that is giving the action a much better feel.
This is the kind of reversal that happens in a bull market.
This stock can become much cheaper if there is a major cycle turn occurring.
The indices need to find support and we need some better pockets of strength.
Latest trial results appear to show the biotech has a super fish oil pill with potential to aid those with high triglycerides.
The market continues to be flat as we enter the last hour of the trading week. It looks like the SCOTUS nomination fight will drag out for at least another divisive week as a couple of Republican senators cave in supporting another FBI investigatio...
The market is in no mood to give the benefit of the doubt to a stock acting as poorly as Facebook.
Big-cap FAANG names and Apple, in particular, were the beneficiaries.
For equity holders in Amarin, now's the time to be implementing my 'Jensen Rules.'